GoodRx vs. Hims & Hers Health: Stagnation vs. Growth in Revenue

10.05.26 14:24 Uhr

Werte in diesem Artikel

GoodRx (NASDAQ:GDRX) primarily generates revenue by offering a price comparison tool that helps consumers find geographically relevant pricing and access negotiated discounts on prescription drugs across the United States.While expanding its offerings to include new weight-loss medications and navigating a rejected privacy settlement in federal court, it reported about 21% EBIT margin for the quarter ended Dec. 31, 2025.Hims & Hers Health (NYSE:HIMS) earns its revenue by operating a telehealth network that connects consumers to licensed healthcare professionals, providing medical consultations and ongoing prescription medication subscriptions directly to customers.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

In eigener Sache

Übrigens: US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Quelle: MotleyFool

Nachrichten zu GoodRx Holdings Inc Registered Shs -A-